Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Takeda Pharmaceutical Company Limited
WARNING LETTER
•Takeda Pharmaceutical Company Limited•November 26, 2019

Takeda Pharmaceutical Company Limited – FDA Warning Letter, Nov 26, 2019

Record Details

The FDA issued a Warning Letter to Takeda Pharmaceutical Company Limited following an inspection from November 18-26, 2019, at their Hikari, Yamaguchi facility. The letter identifies significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals, rendering their drug products adulterated under the FD&C Act. The company's December 18, 2019, response to the FDA 483 was deemed inadequate.

Key violations include: 1. **Inadequate Quality Control Unit (QCU) procedures (21 CFR 211.22(d)):** The QCU allowed aseptic manufacturing to resume after a shutdown without performing a required aseptic process simulation (media fill), leading to the shipment of affected batches to the U.S. market. The FDA requires a comprehensive assessment of the QCU's authority and resources, oversight provisions, batch review processes, and a risk assessment of distributed products. 2. **Failure to establish and follow appropriate written procedures for preventing microbiological contamination (21 CFR 211.113(b)):** * **Inadequate Aseptic Processing Simulations (Media Fills):** The media fill program lacked assurance of preventing microbial contamination, with integral units removed from media fills without adequate justification and insufficient incorporation of commercial production risks, such as the manually intensive (b)(4) operation. * **Poor Aseptic Behavior:** Operators

Company
Takeda Pharmaceutical Company Limited
Inspection date
November 26, 2019
Product type
Drugs
Office
Center for Drug Evaluation and Research
Person
  • Francis Godwin (Director)
View Company Profile

ID · 9d0b36fb-235a-4c11-a81c-905de7fca22f

Violation Codes9
21 CFR 21021 CFR 21121 CFR 211.22(d)21 CFR 211.113(b)21 CFR 211.192FD&C Act 801(a)(3)FD&C Act 501(a)(2)(B)21 U.S.C. 381(a)(3)21 U.S.C. 351(a)(2)(B)

Full citation text and observation details available on the Dashboard.

Other documents for Takeda Pharmaceutical Company Limited
  • 483 - 2019-08-09August 9, 2019
  • 483 - 2015-09-18September 18, 2015
  • 483 - 2010-09-14September 14, 2010

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Takeda Pharmaceutical Company Limited
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.